2018 Coronary Restenosis Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Coronary Restenosis Market
Coronary restenosis refers to a heart condition in which the luminous diameter decreases by more than 50% after the percutaneous coronary intervention. After a patients’ artery is opened through angioplasty or by placing a stent, it again starts closing again in Coronary restenosis. The three phases of the condition include acute recoil, injuries caused by stents can make collagen in the subintimal space, and movement of muscle cells and fibroblasts into this space.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Coronary Restenosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Coronary Restenosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Coronary Restenosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Coronary Restenosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Coronary Restenosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Coronary Restenosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 CORONARY RESTENOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Coronary Restenosis Pipeline Snapshot
2.3 Coronary Restenosis Pipeline by Phase
2.4 Coronary Restenosis Pipeline by Company
2.5 Coronary Restenosis Pipeline by Mechanism of Action
3 CORONARY RESTENOSIS- COMPANY WISE PIPELINE ANALYSIS
AnGes MG
BioRest Ltd.
CytoTools AG
XBiotech Inc
4 CORONARY RESTENOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN CORONARY RESTENOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 CORONARY RESTENOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Coronary Restenosis Pipeline Snapshot
2.3 Coronary Restenosis Pipeline by Phase
2.4 Coronary Restenosis Pipeline by Company
2.5 Coronary Restenosis Pipeline by Mechanism of Action
3 CORONARY RESTENOSIS- COMPANY WISE PIPELINE ANALYSIS
AnGes MG
BioRest Ltd.
CytoTools AG
XBiotech Inc
4 CORONARY RESTENOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN CORONARY RESTENOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Coronary Restenosis Pipeline by Phase, H2- 2018
Figure 2: Coronary Restenosis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Coronary Restenosis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Coronary Restenosis Pipeline by Phase, H2- 2018
Figure 2: Coronary Restenosis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Coronary Restenosis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Coronary Restenosis Pipeline by Phase, H2- 2018
Coronary Restenosis Pipeline by Companies, H2- 2018
Coronary Restenosis Pipeline by Mechanism of Action, H2- 2018
Table 1: AnGes MG Coronary Restenosis Pipeline Drugs, H2- 2018
Table 2: BioRest Ltd. Coronary Restenosis Pipeline Drugs, H2- 2018
Table 3: CytoTools AG Coronary Restenosis Pipeline Drugs, H2- 2018
Table 4: XBiotech Inc Coronary Restenosis Pipeline Drugs, H2- 2018
Coronary Restenosis Pipeline by Phase, H2- 2018
Coronary Restenosis Pipeline by Companies, H2- 2018
Coronary Restenosis Pipeline by Mechanism of Action, H2- 2018
Table 1: AnGes MG Coronary Restenosis Pipeline Drugs, H2- 2018
Table 2: BioRest Ltd. Coronary Restenosis Pipeline Drugs, H2- 2018
Table 3: CytoTools AG Coronary Restenosis Pipeline Drugs, H2- 2018
Table 4: XBiotech Inc Coronary Restenosis Pipeline Drugs, H2- 2018
